Market Overview

Pluristem to Present New Data on PLX-R18 at ASH Annual Meeting


Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced that Dr. Racheli Ofir, Vice President Research & Intellectual Property, will present new data on PLX-R18 cells at the American Society of Hematology's (ASH) 57th Annual Meeting to be held in Orlando, Florida, from December 5-8, 2015.

The poster presentation titled "Mechanism of Action of PLX-R18, a Placental-Derived Cellular Therapy for the Treatment of Radiation-Induced Bone Marrow Failure", will be delivered during Program Session 508: Bone Marrow Failure, on December 6, 2015, at 8:00 PM. The poster will describe data from preclinical studies on irradiated mice showing the mechanism of action by which PLX-R18 cells mitigate the damage to bone marrow caused by exposure to high levels of radiation, such as could occur in a nuclear catastrophe. The poster abstract will be published online in the December 3, 2015 supplemental volume of Blood, a peer-reviewed medical journal published by ASH. The mechanism of action was revealed through a series of trials conducted in conjunction with Charité Universitätsmedizin Berlin Institute of Medical Immunology, the Brandenburg Center of Regenerative Therapy in Berlin, the

See full press release

Posted-In: News M&A Press Releases


Related Articles (PSTI)

View Comments and Join the Discussion!

GE Launches New Renewable Energy Business

Earnings Scheduled For November 17, 2015